Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to twelve new employees under its 2024 Inducement Plan. The awards, approved by the Compensation Committee on January 13, 2025, include non-qualified stock options to purchase 23,782 shares at $17.90 per share and 13,928 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting at the second anniversary and the remaining 50% in two equal annual installments thereafter. Both awards are contingent on continued employment with Acadia.
The company specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage pipeline includes programs for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals (NASDAQ: ACAD) ha assegnato premi di indennità a dodici nuovi dipendenti nell'ambito del suo Piano di Indennità 2024. I premi, approvati dal Comitato per la Compensazione il 13 gennaio 2025, includono opzioni su azioni non qualificate per l'acquisto di 23.782 azioni a $17,90 ciascuna e 13.928 unità di azioni vincolate (RSU).
Le opzioni su azioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto mensilmente per 36 mesi. Le RSU matureranno in quattro anni, con il 50% che matura al secondo anniversario e il restante 50% in due rate annuali uguali in seguito. Entrambi i premi sono soggetti a mantenimento del lavoro presso Acadia.
L'azienda è specializzata in scoperte nel campo delle neuroscienze e ha sviluppato trattamenti approvati dalla FDA per la psicosi da Parkinson e per la sindrome di Rett. Il loro pipeline in fase clinica comprende programmi per la sindrome di Prader-Willi, la psicosi da Alzheimer e altri sintomi neuropsichiatrici nei disturbi del sistema nervoso centrale.
Acadia Pharmaceuticals (NASDAQ: ACAD) ha otorgado premios de inducimiento a doce nuevos empleados bajo su Plan de Inducimiento 2024. Los premios, aprobados por el Comité de Compensación el 13 de enero de 2025, incluyen opciones sobre acciones no calificadas para adquirir 23,782 acciones a $17.90 por acción y 13,928 unidades de acciones restringidas (RSUs).
Las opciones sobre acciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el resto mensualmente durante 36 meses. Las RSUs se consolidarán durante cuatro años, con el 50% consolidándose en el segundo aniversario y el 50% restante en dos pagos anuales iguales posteriormente. Ambos premios están condicionados a la continuación del empleo en Acadia.
La empresa se especializa en avances en neurociencia y ha desarrollado tratamientos aprobados por la FDA para la psicosis de la enfermedad de Parkinson y la síndrome de Rett. Su pipeline en etapa clínica incluye programas para el síndrome de Prader-Willi, la psicosis de Alzheimer y otros síntomas neuropsiquiátricos en trastornos del sistema nervioso central.
아카디아 제약 (NASDAQ: ACAD)는 2024 유인 계획에 따라 12명의 신규 직원에게 유인 보상을 부여했습니다. 이 보상은 2025년 1월 13일 보상 위원회에 의해 승인되었으며, 각각 $17.90에 23,782주를 구매할 수 있는 비자격 주식 옵션과 13,928주의 제한 주식 단위(RSU)를 포함합니다.
주식 옵션은 4년에 걸쳐 성과가 인정되며, 1년 후 25%가 성과로 인정되고 나머지는 36개월 간 월별로 인정됩니다. RSU는 4년에 걸쳐 성과가 인정되며, 2주년 기념일에 50%가 성과로 인정되고 이후 두 개의 동일한 연간 할부로 나머지 50%가 성과로 인정됩니다. 두 보상은 아카디아에서의 계속된 고용을 조건으로 합니다.
회사는 신경과학의 발전을 전문으로 하며 파킨슨병 정신병 및 레트 증후군에 대한 FDA 승인 치료제를 개발했습니다. 그들의 임상 단계 파이프라인에는 프라더-윌리 증후군, 알츠하이머병 정신병 및 기타 중추신경계 장애의 신경정신과 증상 프로그램이 포함됩니다.
Acadia Pharmaceuticals (NASDAQ: ACAD) a accordé des primes d'induction à douze nouveaux employés dans le cadre de son Plan d'induction 2024. Les primes, approuvées par le Comité de rémunération le 13 janvier 2025, comprennent des options d'achat d'actions non qualifiées pour l'acquisition de 23 782 actions à 17,90 $ chacune et 13 928 unités d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises sur quatre ans, avec 25 % acquises après un an et le reste mensuellement pendant 36 mois. Les RSU seront acquises sur quatre ans, avec 50 % devenant acquises au deuxième anniversaire et les 50 % restants en deux versements annuels égaux par la suite. Les deux primes sont conditionnées au maintien de l'emploi chez Acadia.
L'entreprise se spécialise dans les percées en neurosciences et a développé des traitements approuvés par la FDA pour la psychose liée à la maladie de Parkinson et le syndrome de Rett. Leur pipeline en phase clinique comprend des programmes pour le syndrome de Prader-Willi, la psychose de la maladie d'Alzheimer et d'autres symptômes neuropsychiatriques dans les troubles du système nerveux central.
Acadia Pharmaceuticals (NASDAQ: ACAD) hat im Rahmen seines Induktionsplans 2024 Anreizangebote an zwölf neue Mitarbeiter gewährt. Die Angebote, die am 13. Januar 2025 vom Vergütungsausschuss genehmigt wurden, umfassen nicht-qualifizierte Aktienoptionsscheine zum Kauf von 23.782 Aktien zu einem Preis von 17,90 $ pro Aktie und 13.928 eingeschränkte Aktieneinheiten (RSUs).
Die Aktienoptionsscheine werden über einen Zeitraum von vier Jahren erdient, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate erdient wird. Die RSUs werden über vier Jahre erdient, wobei 50 % am zweiten Jahrestag fällig werden und die verbleibenden 50 % anschließend in zwei gleichen jährlichen Raten ausgezahlt werden. Beide Angebote sind an die Fortsetzung des Beschäftigungsverhältnisses bei Acadia gebunden.
Das Unternehmen ist auf Durchbrüche in der Neurowissenschaft spezialisiert und hat von der FDA genehmigte Behandlungen für die Psychose bei Parkinson und das Rett-Syndrom entwickelt. Ihre klinische Pipeline umfasst Programme für das Prader-Willi-Syndrom, die Psychose bei Alzheimer und weitere neuropsychiatrische Symptome bei ZNS-Erkrankungen.
- Expansion of workforce with twelve new hires indicates company growth
- Established vesting schedule promotes long-term employee retention
- Company has FDA-approved products in market for Parkinson's disease psychosis and Rett syndrome
- Active clinical-stage pipeline targeting multiple CNS disorders
- Stock-based compensation will result in dilution for existing shareholders
Each stock option has an exercise price per share equal to
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250117420467/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
What inducement grants did ACAD issue on January 13, 2025?
What is the vesting schedule for ACAD's January 2025 stock options?
How will ACAD's RSUs granted in January 2025 vest?
What therapeutic areas does ACAD currently focus on?
What was the exercise price for ACAD's January 2025 stock options?
